Onorato, EM,
Alamanni, F,
Muratori, M,
Smolka, G,
Wojakowski, W,
Pysz, P,
Zorinas, A,
Zakarkaite, D,
Eltchaninoff, H,
Litzer, PY,
Godart, F,
Calvert, P,
Christou, C,
Mussayev, A,
Missiroli, B,
Buzaev, I,
Curello, S,
Tesorio, T,
Bartorelli, AL (2022) or severe
heart failure (HF), classified as New York
Heart Association (NYHA) class III/IV, decreased from
Levodopa is the most effective drug for the treatment of Parkinson's
disease (PD). After about 5
Survival of patients with lymphoproliferative
diseases increases.
For effective treatment we should
neurodegenerative
diseases, including Parkinson’s and Alzheimer’s
diseases. In the last few years, a number
Isaeva, A,
Averyanov, S,
Iskhakov, I,
Galimov, S,
Galimova, E,
Kiniabaev, T (2021) diseases, as well as for finding the safest and most effective drugs with different mechanisms of action
not only in patients at risk (with a history of inflammatory periodontal
diseases), but also in other
Background objectives: Chronic obstructive pulmonary
disease (COPD) is a complex chronic